Twist Bioscience (TWST) CEO awarded 168,976 PSUs; owns 770,188

Twist Bioscience (TWST) reported an insider equity award for its CEO and director, Emily M. Leproust.

Rhea-AI Filing Summary

Twist Bioscience (TWST) reported an insider equity award for its CEO and director, Emily M. Leproust. On 10/28/2025, she acquired 168,976 shares of common stock at $0, tied to Performance Stock Units whose target criteria were determined to have been met. The filing notes that 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration under the award agreement.

Following the transaction, Leproust beneficially owns 770,188 shares directly. The filing also lists existing employee stock options, including grants with exercise prices of $8.82, $26.66, $23.33, and $67.85, with various vesting and expiration terms as disclosed.

Insider Trade Summary

Grant/Award: 168,976 shares

Grant/Award 6 txns

Insider Leproust Emily M.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	168,976	$0.00	$0.00
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--

Holdings After Transaction: Common Stock — 770,188 shares (Direct); Employee Stock Option (right to buy) — 64,950 contracts (Direct)

Footnotes (6)

1. F1. Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement.
2. F2. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
3. F3. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
4. F4. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
5. F5. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
6. F6. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

FAQ

What did TWST disclose about its CEO's equity on this Form 4?

Emily M. Leproust acquired 168,976 common shares at $0 on 10/28/2025 from PSUs with targets met; 60% vest on 10/01/2026.

How many TWST shares does the CEO own after this transaction?

Following the transaction, Emily M. Leproust beneficially owns 770,188 shares directly.

What are the vesting details for the awarded PSUs at TWST?

The PSUs’ target criteria were met on 10/28/2025. 60% remain subject to time-based vesting and will vest on 10/01/2026, subject to continued service.

Were there any prices associated with the TWST stock acquisition?

Yes. The 168,976 shares were acquired at a $0 price as part of PSU settlement mechanics.

What TWST stock options are listed for the CEO?

Employee stock options are listed with exercise prices of $8.82, $26.66, $23.33, and $67.85, with vesting and expiration terms noted.

When will the remaining PSUs for TWST’s CEO vest?

The remaining 60% are scheduled to vest on October 1, 2026, subject to continued service or acceleration per the award agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/30/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leproust Emily M.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/28/2025		A		168,976(1)	A	$0	770,188	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.95							(2)	09/28/2025	Common Stock	0		0	D
Employee Stock Option (right to buy)	$8.82							(3)	09/28/2027	Common Stock	0		150,879	D
Employee Stock Option (right to buy)	$26.66							(4)	11/18/2028	Common Stock	0		266,539	D
Employee Stock Option (right to buy)	$23.33							(5)	10/23/2029	Common Stock	0		131,290	D
Employee Stock Option (right to buy)	$67.85							12/19/2022	08/31/2030	Common Stock	64,950		64,950(6)	D

Explanation of Responses:

1. Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement.

2. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

3. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

4. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

5. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

6. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.